MedTrace Logo

Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis

NCT05477446 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-07-28

No results posted yet for this study

Summary

This is a single-arm study to evaluate the efficacy and safety of CD207 targeted CAR-T cell therapy in relapsed and refractory langerhans cell histiocytosis.

Conditions

  • Langerhans Cell Histiocytosis

Interventions

BIOLOGICAL

CD207 CAR-T cells

Single dose of CD207 CAR-T cells administered IV

Sponsors & Collaborators

  • Beijing Boren Hospital

    collaborator OTHER

  • Beijing Friendship Hospital

    lead OTHER

Principal Investigators

  • ZHAO Wang, MD · Beijing Friendship Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2025-06-01
Completion
2025-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05477446 on ClinicalTrials.gov